In this article, we will discuss Olaparib (Clinical Trials Experience-2). So, let’s get started. Maintenance Treatment of Recurrent Ovarian Cancer SOLO-2 The safety of Olaparib for the maintenance treatment of patients with platinum sensitive gBRCAm ovarian cancer was investigated in SOLO-2. This study was a placebo-controlled, double-blind study in which 294 patients received either Olaparib […]
Tag: Olaparib
In this article, we will discuss Olaparib (Clinical Trials Experience-1). So, let’s get started. Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the […]
In this article, we will discuss Olaparib (Adverse Reactions). So, let’s get started. Adverse Reactions: The following adverse reactions are discussed elsewhere in the labeling: • Myelodysplastic Syndrome/Acute Myeloid Leukemia • Pneumonitis
In this article, we will discuss Olaparib (Warnings-4). So, let’s get started. Embryo-Fetal Toxicity Olaparib can cause fetal harm when administered to a pregnant woman based on its mechanism of action and findings in animals. In an animal reproduction study, administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and embryo-fetal […]
In this article, we will discuss Olaparib (Warnings-3). So, let’s get started. Pneumonitis, including fatal cases, occurred in <1% of patients treated with Olaparib. If patients present with new or worsening respiratory symptoms such as dyspnea, cough and fever, or a radiological abnormality occurs, interrupt Olaparib treatment and promptly assess the source of the symptoms. […]
In this article, we will discuss Olaparib (Warnings-2). So, let’s get started. Do not start Olaparib until patients have recovered from hematological toxicity caused by previous chemotherapy (≤ Grade 1). Monitor complete blood count for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment. For prolonged hematological toxicities, interrupt Olaparib and monitor […]